ClinicalTrialsFinder
RecruitingPhase 2NCT05291845

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy

Sponsor

Zagazig University

Enrollment

162 participants

Start Date

Apr 3, 2022

Study Type

INTERVENTIONAL

Conditions

Human Papilloma VirusWarts

Summary

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Eligibility

Min Age: 9 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Bivalent HPV vaccine and a biological treatment called Candida antigen vaccine for people with human papilloma virus and warts. The study is currently recruiting participants at 1 location. People eligible for this study include aged 9 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCandida antigen vaccine

we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group

BIOLOGICALBivalent HPV vaccine

we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group

Locations(1)

Reham Essam

Zagazig, Al Sharqia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05291845

Related Trials

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

NCT008672691 location

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NCT009677851 location

Merck IIT: RRP Pembro and Lenvatinib

NCT046456021 location

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

NCT033518551 location

HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks

NCT064140571 location